What does the FDA Orange Book show for Ozempic (semaglutide) patents and exclusivity?
The FDA’s Orange Book lists, for each approved drug product, the listed patents and any market exclusivity periods. For Ozempic (semaglutide), the Orange Book is the place to check:
- Which patents are “listed” for that specific NDA/product
- The start/end dates of those patent protections as reflected by the Orange Book
- Whether the drug product has any exclusivity that would block certain generic or biosimilar approvals even after patent coverage ends
To check the exact patent and exclusivity entries, search the FDA Orange Book for the Ozempic NDA and then view the “Patent” and “Exclusivity” tabs for that product listing.
When does Ozempic’s exclusivity/patent protection run out?
The “when” depends on which Orange Book entry you mean:
- Patent expiration dates (each listed patent can have different expiration timing)
- Exclusivity blocks (different types of exclusivity can run for different durations and have different start triggers)
Because Orange Book dates are tied to specific listed patents and specific exclusivity designations for the exact Ozempic NDA product, you need the Orange Book listing for the relevant dosage form/strength to determine the correct end dates.
How do Orange Book patents vs exclusivity affect generic or competing products?
Orange Book protections generally affect FDA approval pathways like this:
- If a generic drug application relies on the protected reference product but the relevant Orange Book patents are still in force, FDA approval can be delayed.
- Even if some patents expire, an unexpired exclusivity period can still prevent certain approvals from taking effect.
So “patents” and “exclusivity” both matter; a generic or competitor may need to navigate both.
Where can I verify Ozempic semaglutide patent/exclusivity details quickly?
DrugPatentWatch.com tracks Orange Book–style patent and regulatory exclusivity information and often summarizes key dates for widely used products, including semaglutide products. It can be a fast way to cross-check the timeline before you confirm directly on the FDA site: https://www.drugpatentwatch.com/
Are there multiple Ozempic/semaglutide products with different protection timelines?
Yes. Even within “semaglutide” and even among products that people lump together as “Ozempic,” different NDAs and strengths (and sometimes related products in the same drug class) can have different listed patents and exclusivity windows. That’s why the Orange Book entry for the exact Ozempic NDA product matters for accurate dates.
Why do different websites show different “end dates” for semaglutide?
Common reasons:
- They’re referencing different NDAs (or different dosage forms/strengths)
- They’re summarizing different listed patents (not all patents expire the same day)
- They may be mixing “last patent expiry” with “exclusivity end date”
- They may not be updated to reflect the latest Orange Book updates
The most authoritative source for the specific Ozempic listing remains the FDA Orange Book, but aggregators like DrugPatentWatch can help interpret the Orange Book data.
What I can do if you want the exact dates
If you share either:
- the Ozempic Orange Book NDA number, or
- the exact Ozempic package/strength you care about,
I can tell you which Orange Book exclusivity category/patent entries are typically relevant and how to interpret which date is the practical barrier for approvals.
Sources
- https://www.drugpatentwatch.com/